On April 3, 2019 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins) for the treatment of patients with a wide range of solid tumors, reported that Drew Fromkin, President and Chief Executive Officer, will present at Needham & Company’s 18th Annual Healthcare Conference, occurring April 9-10, 2019 in New York City (Press release, Tarveda Therapeutics, APR 3, 2019, View Source [SID1234534967]). Tarveda presentation details:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date: Tuesday, April 9, 2019
Time: 1:10pm Eastern Time
Location: Westin Grand Central, New York, NY